Name of the medicinal product: PRALOTAM

Content: Each film coated tablet contains 40 mg of Citalopram

Pharmaceutical Form: Film-coated tablets

Pharmacotherapeutic group:Antidepressant

Packaging Description: Cardboard box containing 30 tablets in blisters PVC / PVDC - Aluminum foil

PRALOTAM containing citalopram, a bicyclic derivative of naphthalene with antidepressant activity. The citalopram is a selective inhibitor of serotonin reuptake.
PRALOTAM indicated for:
  • A major depressive episode. Prophylactic treatment against relapse and the emergence of new depressive episodes.
  • Panic disorder with or without agoraphobia
  • OCD
Hypersensitivity to the drug or to any of the excipients. Concurrent or recent (less than 14 days) treatment with Monoamine oxidase (MAO) inhibitors.
The citalopram tablets are administered at a dose in the evening.
A major depressive episode and prophylaxis against recurrence and occurrence of new depressive episodes
The usual dose is 20MG once daily. If clinically indicated, the dose is increased to 40mg if necessary to a maximum of 60mg / day. Patients over 65 should take half the recommended dose, ie 10-30mg / day. The antidepressant effect is installed within 2 to 4 weeks. Treatment with antidepressants is symptomatic and must therefore be continued for an appropriate period of time, usually 4-6 months to achieve the stabilization of the result and to prevent recurrences. Patients suffering from recurrent depression, may need to continue treatment for a number of years to prevent new episodes of depression.
Panic disorder
Initially 10mg / day. After one week the dosage was increased to 20MG / day. The optimal dose is typically 20-30mg / day. With an insufficient response, the dose may be increased to a maximum of 60mg / day.
Elderly patients over 65 should take half the recommended dose.
Treatment for panic disorder is long. Maintaining the therapeutic effect has been demonstrated during prolonged treatment (one year).
An initial dose 20MG daily. The dose may be increased by 20MG up to 60mg daily if necessary during clinical evaluation.
Elderly patients over 65 should take half the recommended dose.
The onset of action in the treatment of obsessive compulsive disorder occurs within 2-4 weeks, and the improvement increases with the lapse of time.
Not recommended drug therapy in children and adolescents aged <18 years, because there is no clinical experience to use.
Patients with hepatic insufficiency
Be given a lower dose of the recommended regimen for adults and monitored carefully.
Patients with renal insufficiency
No dose adjustment is required in patients with mild to moderate renal insufficiency. There is no experience in patients with severe renal impairment (creatinine clearance <20ml / min).